{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEGFILGRASTIM&page=4", "query": { "intervention": "PEGFILGRASTIM", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 262, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEGFILGRASTIM&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEGFILGRASTIM&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:19:01.677Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02909036", "title": "Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Amyloidosis" ], "interventions": [ { "name": "Melphalan", "type": "DEVICE" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Autologous Hematopoietic Progenitor Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 46, "start_date": "2016-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02909036" }, { "nct_id": "NCT02650635", "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Melanoma of the Skin", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Colorectal Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02-05", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650635" }, { "nct_id": "NCT04759586", "title": "Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Mediastinal Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 244, "start_date": "2021-10-05", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 215, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04759586" }, { "nct_id": "NCT03273842", "title": "A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "PF-06881894", "type": "BIOLOGICAL" }, { "name": "US-approved Neulasta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 422, "start_date": "2017-10-27", "completion_date": "2018-07-25", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 4, "location_summary": "Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 1 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03273842" }, { "nct_id": "NCT00478361", "title": "Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Distal Urethral Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter", "Stage III Bladder Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder", "Urethral Cancer Associated With Invasive Bladder Cancer" ], "interventions": [ { "name": "Gemcitabine hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2007-04", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 2, "location_summary": "Springfield, Missouri • Houston, Texas", "locations": [ { "city": "Springfield", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478361" }, { "nct_id": "NCT00777673", "title": "Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2008-10", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 3, "location_summary": "Memphis, Tennessee • Fort Worth, Texas", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777673" }, { "nct_id": "NCT03202927", "title": "Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "PEGFILGRASTIM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adello Biologics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 102, "start_date": "2017-03-25", "completion_date": "2018-04-12", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 2, "location_summary": "Tempe, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03202927" }, { "nct_id": "NCT04662892", "title": "An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Febrile Neutropenia", "Non-myeloid Malignancy" ], "interventions": [ { "name": "Pegfilgrastim-Cbqv", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-08-01", "completion_date": "2022-12-15", "has_results": false, "last_update_posted_date": "2020-12-23", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 3, "location_summary": "Charlotte, North Carolina • Myrtle Beach, South Carolina • Rock Hill, South Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "Rock Hill", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04662892" }, { "nct_id": "NCT01313884", "title": "Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Cancer", "Ewing's Sarcoma" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3, "start_date": "2011-05", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313884" }, { "nct_id": "NCT00808639", "title": "Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Muscle-invasive Bladder Cancer" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-12", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-11-15T12:19:01.677Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Burlington, Massachusetts • Pittsburgh, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808639" } ] }